Seeking Alpha on Insurers’ Efficient Investment Frontier

Seeking Alpha on Insurers’ Efficient Investment Frontier

Introducing BNY Mellon’s Insurance Industry Roundtable Series

November 2015
Paul Traynor - Moderator   |   Head of Insurance - International
Michael Gordon - Participant   |   Global Head of Insurance Solutions
Tobias Mensing - Participant   |   Senior Product Strategist
Heneg Parthenay - Participant   |   Head of Insurance, Insight Investment

A panel of our insurance industry experts offer their insights on the evolving European insurance industry. This page provides an overview of the transcript derived from one in a series of Insurance Industry Roundtable discussions in which our executive team and industry and product experts explore key trends and issues facing our insurance industry clients.

Our Insurance Industry Roundtable series considers the challenges facing Insurers in EMEA and how by accessing BNY Mellon’s comprehensive Investment Management and Investment Services solutions we can help them achieve their business objectives. Other topics include:

  • Cash Investments in a Turbulent World
  • Investing in Illiquids: Challenges for Insurance Firms
  • Managing Your Securities Financing & Derivatives Collateral for Optimum Results
  • Transparency: the Data Management Challenge Facing Insurers
  • T2S: Opportunities for Insurers arising from Europe’s New Post-Trade Landscape
  • Using Trusts and Securitisation within Insurance Company Finance
  • Using Your Global Markets Counterparties to Help Optimise Your Risk Profile

PAUL TRAYNOR: Solvency II has had a major impact on the investment strategies of insurance firms in Europe in recent years. Is it still the predominant factor or are there now more significant other forces at play?

HENEG PARTHENAY: Solvency II is still being digested and acted upon, but the major players have largely worked their way through the implications. From an investment perspective, a critical factor is the impact of the European Central Bank’s (ECB) quantitative easing (QE) programme on interest rates in the euro-zone and surrounding economies, including the UK.

As major investors in European government bonds, life insurers will have been pleased by the ECB’s smooth management of interest rate moves to date, but will still be concerned about how the bank exits from the programme. If QE carries on for a long time, insurers will suffer a prolonged period of falling yields in their investment portfolios; but if rates rise sharply, insurers will face a wall of redemptions as their customers move to new policies to benefit from higher-yielding assets. It’s possible to mitigate the latter risk with interest rate swaps, but only if you feel confident about the timing of the next interest rate hike in the Eurozone. In response to lower rates, some insurers have been re-risking their portfolios in search of higher yields and running mismatches despite the capital costs.

PAUL: With the US further along the interest rate curve, what are the main investment challenges for insurers in your home market?

MICHAEL GORDON: Sustained low interest rates have certainly been a concern. Because of its impact on their primary source of income, i.e. investment yields, a prolonged low interest rate environment can slowly bleed an insurance firm to death. But a rapid spike could lead to a quicker demise because of the redemptions and subsequent market value losses from selling off bonds.

As an insurance firm, you have three main concerns: matching assets and liabilities to obtain an appropriate spread, taking into account duration, yield and convexity; optimisation of capital; and securing distribution, through how you price, underwrite and manage your distribution network.

Those latter choices become much harder when yield is low, capital requirements are high and levels of risk and uncertainty are greater.

In response, asset managers should offer special situations arising from the deleveraging and retrenchment of banks and the availability of alternative sources of liquidity and capital, for example sovereigns that need to support elements of their banking systems. Asset managers should look to provide solutions based on the move into direct lending and other banking functions, both short-term financing in the repo markets activity for the treasury function and long-term financing for general account portfolios.

There is also scope for asset managers to develop capital relief vehicles, to provide not only additional capacity but also more capital structure optionality, for example if an insurer wanted to vary asset risk versus insurance risk in accordance to their ability to access to capital via traditional means. Asset managers should help insurers to tap new inflows of capital that seek to exploit insurers’ lower correlation with other available investment returns – particularly where insurers are exposed to incidence risk, more than interest rate risk. Such inflows offer an opportunity to create structures that will provide insurers with more balance sheet and strategic flexibility as they wait to see how capital regimes evolve, potentially making them more competitive today, and giving them capacity for the future. Finally, asset managers should be helping insurers to develop products around innovative investment solutions that would expand distribution.

HENEG: In Europe too, there is definitely an opportunity for long-term investors such as insurers to harvest the ‘illiquidity premium’ by providing capital for the types of lending activity for which banks have a reduced appetite. In contrast to the US, the securitisation market has not yet recovered to pre-crisis levels, but this potentially offers insurers a further opportunity to become an alternative source of funding. We’re also seeing sophisticated clients focusing more closely on cash flow matching when considering their investment options, compared with duration matching. This is partly due to heightened concerns about liquidity conditions in the fixed income markets – even in government bonds – but also because of regulatory changes which are demanding more reporting and transparency on how insurers manage liquidity.

PAUL: How are these European and US trends changing the product range being offered by asset managers?

TOBIAS MENSING: We’re offering a number of alternative products that can provide both diversification for the insurers but also help them harvest the illiquidity premium better than fixed income products, for example products that offer exposure to loans, infrastructure debt and private equity.

HENEG: One of the challenges is that there is no standard way to address cash flow mismatches. You have to add a swap overlay to a classic fixed income portfolio, perhaps widening your instrument universe to achieve returns, but the solution has to be bespoke, based on a clear understanding of the client’s liability profile.

MICHAEL: In future, I think we will see a move away from traditional products to designed solutions that can match the evolving needs that we’ve highlighted earlier in the discussion.

PAUL: How are today’s investment challenges impacting different types of insurers?

MICHAEL: Life insurers are very focused on interest rate risks and have appetite for alternative sources of capital. Annuity providers are under severe strain from trying to grow their businesses at a time when market / longevity covariance risks are placing particular restraints on their capital. To support growth, even the most profitable are increasingly looking for structures that offer capital relief.

Property and casualty (P&C) insurers are generally further advanced than life insurers, both in terms of accessing alternative sources of capital and risk decomposition. To a large extent, insurance is a series of under-priced options. The question is: are they underpriced for good reasons? When helping insurers to find the most efficient ‘homes’ for those decomposed risks, we need to make sure those providers of capital understand the risks, are appropriately compensated for taking them on and that the structures we create do not encourage adverse selection in the long term, which could subsequently cause those capital sources to dry up.

PAUL: P&C firms in Europe have engaged in a re-risking of their balance sheets and hold a much wider spread of investments now. What other changes do you see?

HENEG: They’ve also reconsidered their liquidity needs. Historically, non-life firms have tended to be more liquid than strictly necessary from an investment perspective, but in the low-yield environment, those with the appropriate internal governance and headroom have taken the best available risk/return option by taking on a higher proportion of illiquid assets.

On the life side, greater use of hedging strategies can help to decompose risk. Regulatory reforms are already forcing insurers to separate out their risks into ‘buckets’, which can then potentially be further added to or split for effective risk decomposition purposes, enabling insurers to manage risk components one by one. Another beneficial impact of regulation is that the OTC derivatives typically used to offset these risks are becoming either more heavily collateralised or exchange-traded, which gives the user more security that the derivative will provide efficient protection even in stressed market conditions.

PAUL: Are the investment challenges, priorities and styles of insurance firms converging, both across Europe versus US, and beyond?

HENEG: The underlying economics are the same but other common factors can have different impacts, such as the nature of longevity, the timing of macro-economic recovery and therefore interest-rate rises, plus of course regulation. For example, US insurers are invested in asset-backed securities (ABS) but Solvency II is making this progressively harder in Europe. Conversely, Europe is more flexible in allowing investment in un-rated securities, provided you can demonstrate expertise in credit risk, while US regulators require more dependence on external ratings.

MICHAEL: The underlying risks are the same and so should be the objectives of the solutions provided by asset managers. But providers such as BNY Mellon have to ensure that we structure solutions and vehicles so that they are acceptable in the relevant regulatory environments.

PAUL: In terms of current investments, US insurers have a greater allocation toward corporate debt, while European insurers tend to favour sovereign debt. This may be caused by deeper US corporate debt markets compared to Europe, where a higher proportion of debt funding is sourced from banks traditionally. The prolonged low-yield environment in Europe has led insurers to take on more credit risk, by switching out of sovereign into corporate debt. What other changes and opportunities do you see for insurers?

MICHAEL: Insurers might face lots of pressures but in other respects they are in a position of strength. Given prevailing economic uncertainty, firms that can support long-term investments are really valuable. Because insurers offer a rich source of long-term flexible permanent capital, they have a lot of leverage over borrowers to structure cash flows according to their liquidity needs. As such I see increase overlap between the interests of insurers and the private equity (PE) world. PE firms are finding it increasingly difficult to deploy capital in a way that meets the investment horizons and returns expectations of their clients. But they do have the flexibility and sophistication to structure cash flows from their investments to meet the cash flow needs of insurers.

HENEG: The attributes of insurance firms are very valuable to PE firms that have substantial reach in terms of the money they can raise but cannot offer the same kind of long-term commitment. PE firms are now effectively in the credit space. Their clients are less risk averse than most, so are on the higher-risk side of the market, while insurers can provide the capacity to take up the senior, secured part of the trade. Combined, PE and insurance firms have an opportunity to replace withdrawn bank lending capacity.

MICHAEL: When PE firms started insurance businesses, the PE arm might have been the stronger arm, but as the insurance units generated more float, had less need to mark to market, and had greater access to flexible permanent capital, they have begun to support the PE arm. As such, insurance firms are playing an ever bigger role in providing real money to the economy. They have an unprecedented opportunity to shape the outcomes in the wider economy.

HENEG: In Europe, investment in a leveraged PE vehicle attracts high capital charge under Solvency II, requiring an alternative approach to help insurers tap into PE opportunities. A more capital efficient route for insurers to participate into private equity funding is through fixed income instrument, for matching and regulatory reasons.

MICHAEL: Insurers have the ability to attract and deploy substantial amounts of capital. Historically, they have had outstanding discipline in how they manage their assets and liabilities. As these new opportunities emerge, it is important that firms with the requisite expertise and experience take the lead, rather than retreating to let more aggressive players grab the initiative.

About the Panel

Paul Traynor

Paul Traynor
Head of Insurance Services - International

Paul leads BNY Mellon’s insurance segment efforts across Asia Pac, EMEA and LatAm. He joined the company in 2004, leading the insurance segment for the EMEA region. Prior to joining BNY Mellon, Paul was with PricewaterhouseCoopers for 15 years, latterly running the Investment Management Consultancy Practice.

Paul trained as a Chartered Accountant with PricewaterhouseCoopers and has a B. Comm (Hons) in Business Studies from University College Dublin, Ireland.

 

Michael Gordon

Michael Gordon
Managing Director, Global Head of Insurance Solutions

Michael Gordon is Global Head of Insurance Solutions for BNY Mellon Investment Management. In this role, he is responsible for oversight of the firm’s global institutional insurance distribution efforts, including reinsurance transactions, and specialty solutions businesses, such as home equity retirement solutions.

Prior to joining BNY Mellon in 2013, Michael spent the bulk of his career at New York Life Insurance Company, most notably leading a profit centre encompassing a variety of disciplines, including investment management, actuarial/liability pricing, finance, asset-liability matching, product/platform development, wholesaling, marketing, training, sales, technology and operations/service. These businesses included the largest life insurance business in the U.S., the registered investment advisor and the broker dealer, in addition to significant portions of the career agency distribution system. Michael has over 18 years of investment experience and earned a Bachelor of Arts degree in Philosophy from Colgate University.

 

Tobias Mensing

Tobias Mensing
Senior Product Strategist

Tobias joined BNY Mellon in 2008 as Product Development Manager, before moving into his current role as Senior Product Strategist for BNY Mellon Investment Management EMEA. Prior to joining BNY Mellon, Tobias was a Product Development Manager at JP Morgan Asset Management.

Tobias is a CFA® charterholder and has a Master of Science degree from Rutgers University (NJ).

 

Heneg Parthenay

Heneg Parthenay
Head of Insurance - Insight Investment

Heneg joined Insight Investment as Head of Insurance in January 2015, following a previous role as Head of Insurance for BNY Mellon Investment Management EMEA. Prior to joining BNY Mellon, Heneg spent eight years at Aviva, holding a range of corporate development and capital management positions. Prior to Aviva, Heneg worked in the Insurance division of Renault and was asset liability manager for the Global Corporate Insurance Division of AXA.

Heneg holds a Masters in Finance, Banking and Insurance, and a Masters in Risk Management from Paris Dauphine University. He also holds a Masters in Actuarial Science and is a Fellow of the French Institute of Actuaries.

 

BNY Mellon is the corporate brand of The Bank of New York Mellon Corporation and may be used as a generic term to reference the corporation as a whole and/or its various subsidiaries generally. This material and any products and services may be issued or provided under various brand names in various countries by duly authorised and regulated subsidiaries, affiliates, and joint ventures of BNY Mellon, which may include any of the following. The Bank of New York Mellon, 225 Liberty St, New York, New York 10286 USA, a banking corporation organised pursuant to the laws of the State of New York, and operating in England through its branch at One Canada Square, London E14 5AL UK, registered in England and Wales with numbers FC005522 and BR000818. The Bank of New York Mellon is supervised and regulated by the New York State Department of Financial Services and the US Federal Reserve and authorised by the Prudential Regulation Authority. The Bank of New York Mellon, London Branch is subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. The Bank of New York Mellon SA/NV, a Belgian public limited liability company, with company number 0806.743.159, whose registered office is at 46 Rue Montoyerstraat, B-1000 Brussels, Belgium, authorised and regulated as a significant credit institution by the European Central Bank (ECB), under the prudential supervision of the National Bank of Belgium (NBB) and under the supervision of the Belgian Financial Services and Markets Authority (FSMA) for conduct of business rules, a subsidiary of The Bank of New York Mellon, and operating in England through its branch at 160 Queen Victoria Street, London EC4V 4LA, registered in England and Wales with numbers FC029379 and BR014361. The Bank of New York Mellon SA/NV (London Branch) is authorised by the ECB, NBB and the FSMA and subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and Prudential Regulation Authority are available from us on request. The Bank of New York Mellon, Singapore Branch is subject to regulation by the Monetary Authority of Singapore. The Bank of New York Mellon, Hong Kong Branch is subject to regulation by the Hong Kong Monetary Authority and the Securities & Futures Commission of Hong Kong. The Bank of New York Mellon Securities Company Japan Ltd acts as intermediary for The Bank of New York Mellon. Not all products and services are offered at all locations.

The material contained in this document, which may be considered advertising, is for general information and reference purposes only and is not intended to provide legal, tax, accounting, investment, financial or other professional advice on any matter, and is not to be used as such. The contents may not be comprehensive or up-to-date, and BNY Mellon will not be responsible for updating any information contained within this document. If distributed in the UK or EMEA, this document is a financial promotion. This document and the statements contained herein, are not an offer or solicitation to buy or sell any products(including financial products) or services or to participate in any particular strategy mentioned and should not be construed as such. This document is not intended for distribution to, or use by, any person or entity in any jurisdiction or country in which such distribution or use would be contrary to local law or regulation. Similarly, this document may not be distributed or used for the purpose of offers or solicitations in any jurisdiction or in any circumstances in which such offers or solicitations are unlawful or not authorised, or where there would be, by virtue of such distribution, new or additional registration requirements. Persons into whose possession this document comes are required to inform them about and to observe any restrictions that apply to the distribution of this document in their jurisdiction. The information contained in this document is for use by wholesale clients only and is not to be relied upon by retail clients.

Trademarks, service marks and logos belong to their respective owners.

The views expressed herein are those of the contributors only and may not reflect the views of BNY Mellon.

© 2015 The Bank of New York Mellon Corporation. All rights reserved.